NCT01697111 - Comparative Study of BAY86-5300 With an Extended Flexible Regimen for Endometriosis | Biotech Hunter

Enrollment

312

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

March 31, 2014

Study Completion Date

December 31, 2014

Conditions

Endometriosis

Interventions

DRUG

EE20/DRSP(BAY86-5300)

One tablet \[0.02 mg of ethinylestradiol (β-CDC) and 3 mg of drospirenone\] / day

DRUG

Placebo

One tablet (no active ingredient) / day and one tablet \[0.02 mg of ethinylestradiol (β-CDC) and 3 mg of drospirenone\] / day, for the first 24 weeks and the later 28 weeks, respectively

DRUG

Dienogest

Dienogest 1mg twice a day (bid)

Trial Locations (32)

446-8510

Anjo

491-8551

Ichinomiya

451-8511

Nagoya

460-0011

Nagoya

464-0066

Nagoya

270-2267

Matsudo

910-0845

Fukui-shi

910-8526

Fukui-shi

500-8717

Gifu

370-0883

Takasaki

664-8540

Itami

666-0125

Kawanishi

654-0047

Kobe

920-8530

Kanazawa

247-8533

Kamakura

212-0016

Kawasaki

230-0001

Yokohama

231-0023

Yokohama

530-0001

Osaka

530-0013

Osaka

542-0086

Osaka

560-0022

Toyonaka

364-8501

Kitamoto

112-0014

Bunkyo

104-0061

Chuo-ku

183-0056

Fuchū

192-0046

Hachiōji

194-0022

Machida

105-0001

Minato

107-0051

Minato

188-0011

Nishitōkyō

175-0092

tabashi City